Logo image of TSBX

TURNSTONE BIOLOGICS CORP (TSBX) Stock Fundamental Analysis

NASDAQ:TSBX - Nasdaq - US90042W1009 - Common Stock - Currency: USD

0.3609  0 (-0.3%)

After market: 0.3599 0 (-0.28%)

Fundamental Rating

2

Taking everything into account, TSBX scores 2 out of 10 in our fundamental rating. TSBX was compared to 558 industry peers in the Biotechnology industry. While TSBX seems to be doing ok healthwise, there are quite some concerns on its profitability. TSBX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TSBX had negative earnings in the past year.
In the past year TSBX has reported a negative cash flow from operations.
TSBX Yearly Net Income VS EBIT VS OCF VS FCFTSBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -228.20%, TSBX is not doing good in the industry: 90.32% of the companies in the same industry are doing better.
TSBX has a Return On Equity of -315.29%. This is in the lower half of the industry: TSBX underperforms 72.40% of its industry peers.
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROIC N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TSBX Yearly ROA, ROE, ROICTSBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

TSBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSBX Yearly Profit, Operating, Gross MarginsTSBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

TSBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSBX has been reduced compared to 1 year ago.
TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSBX Yearly Shares OutstandingTSBX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M
TSBX Yearly Total Debt VS Total AssetsTSBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -18.71, we must say that TSBX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TSBX (-18.71) is worse than 83.51% of its industry peers.
TSBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.71
ROIC/WACCN/A
WACC9.71%
TSBX Yearly LT Debt VS Equity VS FCFTSBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 3.70 indicates that TSBX has no problem at all paying its short term obligations.
TSBX has a Current ratio of 3.70. This is comparable to the rest of the industry: TSBX outperforms 43.55% of its industry peers.
TSBX has a Quick Ratio of 3.70. This indicates that TSBX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.70, TSBX perfoms like the industry average, outperforming 45.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.7
TSBX Yearly Current Assets VS Current LiabilitesTSBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

TSBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.08%, which is quite impressive.
TSBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)73.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.30% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TSBX Yearly Revenue VS EstimatesTSBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 20M 40M 60M 80M 100M
TSBX Yearly EPS VS EstimatesTSBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TSBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TSBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSBX Price Earnings VS Forward Price EarningsTSBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSBX Per share dataTSBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

TSBX's earnings are expected to grow with 35.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TURNSTONE BIOLOGICS CORP

NASDAQ:TSBX (7/18/2025, 8:16:47 PM)

After market: 0.3599 0 (-0.28%)

0.3609

0 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-13 2025-08-13/amc
Inst Owners39.43%
Inst Owner Change1%
Ins Owners3.83%
Ins Owner ChangeN/A
Market Cap8.35M
Analysts43.33
Price Target1.02 (182.63%)
Short Float %1.83%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.94%
Min EPS beat(2)-92.31%
Max EPS beat(2)20.43%
EPS beat(4)3
Avg EPS beat(4)-13.3%
Min EPS beat(4)-92.31%
Max EPS beat(4)20.43%
EPS beat(8)4
Avg EPS beat(8)-29.72%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-2.73
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.47
OCFYN/A
SpS0
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -228.2%
ROE -315.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.15%
ROA(5y)N/A
ROE(3y)-108.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.7
Altman-Z -18.71
F-Score4
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)63.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y77.07%
EPS Next 2Y35.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.71%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.49%
OCF growth 3YN/A
OCF growth 5YN/A